Biocon Biologics has secured market entry for its proposed biosimilar Bmab 1200 in Europe, UK, Canada, and Japan by signing a settlement agreement with Janssen, facilitating its commercialization after resolving patent disputes. The reference product Stelara(r) had global sales of $10.85 billion in 2023.